C2 PHARMA Receives C-DMF approval for Brimonidine Tartrate
Cork, Ireland – March 05, 2026 – C2 PHARMA the global leader in ophtalmic active pharmaceutical ingredients (APIs), announces the approval of C-DMF for Brimonidine Tartrate.
This regulatory milestone further strengthens C2 PHARMA’s ophthalmic portfolio and supports our partners in accelerating product development and regulatory submissions in China and other markets relying on the Chinese Drug Master File system.
The availability of a C-DMF allows pharmaceutical companies to streamline their registration pathways while relying on C2 PHARMA’s established manufacturing and regulatory expertise.
With a broad portfolio of ophthalmic APIs including Latanoprost, Timolol Maleate, Pilocarpine, Tropicamide and other essential molecules for ophthalmic formulations, C2 PHARMA continues to support partners worldwide with high-quality and reliable supply.
Meet the C2 PHARMA team during DCAT Week in New York from March 23 to March 26 at the Benjamin Hotel, Suite 2202, to discuss this development and explore collaboration opportunities.
For meeting requests or further information, please contact : info@c2pharma.com
About C2 PHARMA
C2 PHARMA is the global leader in ophthalmic active pharmaceutical ingredients (APIs). Founded in 2014 and headquartered in Cork, Ireland, C2 PHARMA ensures a consistent supply of high-quality APIs at competitive prices, serving over 200 pharmaceutical companies worldwide. Their specialized affiliate, Logistics4Pharma (Frankfurt, Germany), provides tailored GDP-compliant cold-chain logistics solutions.
Media Contact
Serge Tarabay